Page 50 - 2020_09-Haematologica-web

P. Bianchi and E. Fermo
Folia Haematol Int Mag Klin Morphol
Blutforsch. 1965;83(4):366-376. 59.Max-Audit I, Rosa R, Marie J. Pyruvate
kinase hyperactivity genetically determined: metabolic consequences and molecular char- acterization. Blood. 1980;56(5):902-909.
1994;48(3):149-163.
74. Finkenstedt A, Bianchi P, Theurl I, et al.
Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br J Haematol. 2009;144(5):789- 793.
75. Goto T, Ubukawa K, Kobayashi I, et al. ATP produced by anaerobic glycolysis is essential for enucleation of human erythroblasts. Exp Hematol. 2019;72:14-26.e1
76. van Beers EJ, van Straaten S, Morton DH, et al. Prevalence and management of iron over- load in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica. 2019;104(2):e51-e53.
77. Zanella A, Berzuini A, Colombo MB, et al. Iron status in red cell pyruvate kinase defi- ciency: study of Italian cases. Br J Haematol. 1993;83(3):485-490.
78. Mojzikova R, Koralkova P, Holub D, et al. Iron status in patients with pyruvate kinase deficiency: neonatal hyperferritinaemia associated with a novel frameshift deletion in the PKLR gene (p.Arg518fs), and low hep- cidin to ferritin ratios. Br J Haematol. 2014;165(4):556-563.
79. Zanella A, Bianchi P, Iurlo A, et al. Iron status and HFE genotype in erythrocyte pyruvate kinase deficiency: study of Italian cases. Blood Cells Mol Dis. 2001;27(3):653-661.
80.Rider NL, Strauss KA, Brown K, et al. Erythrocyte pyruvate kinase deficiency in an old-order Amish cohort: longitudinal risk and disease management. Am J Hematol. 2011;86(10):827-834.
81.Grace RF, Zanella A, Neufeld EJ, et al. Erythrocyte pyruvate kinase deficiency: 2015 status report. Am J Hematol. 2015;90 (9):825-830.
82. Perseu L, Giagu N, Satta S, et al. Red cell pyruvate kinase deficiency in Southern Sardinia. Blood Cells Mol Dis. 2010;45(4): 280-283.
83.Branca R, Costa E, Rocha S, et al. Coexistence of congenital red cell pyruvate kinase and band 3 deficiency. Clin Lab Haematol. 2004;26(4):297-300.
84. Christensen RD, Yaish HM, Nussenzveig RH, Agarwal AM. Siblings with severe pyru- vate kinase deficiency and a complex geno- type. Am J Med Genet A. 2016;170(9):2449- 2452.
85. Vercellati C, Marcello AP, Fermo E, et al. A case of hereditary spherocytosis misdiag- nosed as pyruvate kinase deficient hemolyt- ic anemia. Clin Lab. 2013;59(3-4):421-424.
86. Fermo E, Vercellati C, Marcello AP, et al. Hereditary xerocytosis due to mutations in piezo1 gene associated with heterozygous pyruvate kinase deficiency and beta-tha- lassemia trait in two unrelated families. Case Rep Hematol. 2017;2017:2769570.
87. Cohen-Solal M, Préhu C, Wajcman H, et al, A new sickle cell disease phenotype associ- ating Hb S trait, severe pyruvate kinase defi- ciency (PK Conakry), and an alpha2 globin gene variant (Hb Conakry). Br J Haematol. 1998;103(4):950-956.
88. Alli N, Coetzee M, Louw V, et al. Sickle cell disease in a carrier with pyruvate kinase deficiency. Hematology. 2008;13(6):369-372.
89. Manco L, Vagace JM, Relvas L, et al. Chronic haemolytic anaemia because of pyruvate kinase (PK) deficiency in a child heterozy-
gous for haemoglobin S and no clinical fea- tures of sickle cell disease. Eur J Haematol. 2010;84(1):89-90.
90. Zarza R, Moscardo M, Alvarez R, et al. Co- existence of hereditary spherocytosis and a new red cell pyruvate kinase variant: PK Mallorca. Haematologica. 2000;85(3):227- 232.
91. van Zwieten R, van Oirschot BA, Veldthuis M, et al. Partial pyruvate kinase deficiency aggravates the phenotypic expression of band 3 deficiency in a family with heredi- tary spherocytosis. Am J Hematol. 2015;90 (3):E35-E39.
92.Pereira J, Gonzalez A, Vagace J, et al. Congenital dyserythropoietic anemia asso- ciated to a GATA1 mutation aggravated by pyruvate kinase deficiency. Ann Hematol. 2016;95(9):1551-1553.
93. van Straaten S, Bierings M, Bianchi P, et al. Worldwide study of hematopoietic allo- geneic stem cell transplantation in pyruvate kinase deficiency. Haematologica. 2018;103 (2):e82-e86.
94. HeY,LuoJ,LeiY,etal.AnovelPKLRgene mutation identified using advanced molecu- lar techniques. Pediatr Transplant. 2018;22 (2): e13143.
95. Shimomura M, Doi T, Nishimura S, et al. Successful allogeneic bone marrow trans- plantation using immunosuppressive condi- tioning regimen for a patient with red blood cell transfusion dependent pyruvate kinase deficiency anemia. Hematol Rep. 2020;12 (1):8305.
96. Yang H, Merica E, Chen Y, et al. Phase 1 sin- gle and multiple-ascending-dose random- ized studies of the safety, pharmacokinetics, and pharmacodynamics of AG-348, a first- in-class allosteric activator of pyruvate kinase R, in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(2):246-259.
97. Rab MAE, van Oirschot BA, Kosinski PA, et al. AG-348 (Mitapivat), an allosteric activa- tor of red blood cell pyruvate kinase, increases enzymatic activity, protein stabili- ty, and ATP levels over a broad range of PKLR genotypes. Haematologica. 2020 Jan 23. [Epub ahead of print]
98. Dunbar CE, High KA, Joung JK, et al. Gene therapy comes of age. Science. 2018;359 (6372):eaan4672.
99. Magrin E, Miccio A, Cavazzana M. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies. Blood. 2019;134(15):1203-1213.
100. Meza NW, Alonso-Ferrero ME, Navarro S, et al. Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme. Mol Ther. 2009;17(12):2000- 2009.
101.Meza NW, Quintana-Bustamante O, Puyet A, et al. In vitro and in vivo expression of human erythrocyte pyruvate kinase in ery- throid cells: a gene therapy approach. Hum Gene Ther. 2007;18(6):502-514.
102. Garcia-Gomez M, Calabria A, Garcia-Bravo M, et al. Safe and efficient gene therapy for pyruvate kinase deficiency. Mol Ther. 2016;24(7):1187-1198.
103.Quintana-Bustamante O, Fañanas-Baquero S, Orman I, et al. Gene editing of PKLR gene in human hematopoietic progenitors through 5' and 3' UTR modified TALEN mRNA. PLoS One. 2019;14(10):e0223775.
60. van Oirschot BA, Francois JJ, van Solinge WW, et al. Novel type of red blood cell pyru- vate kinase hyperactivity predicts a remote regulatory locus involved in PKLR gene expression. Am J Hematol. 2014;89(4):380- 384.
61. Beutler E, Westwood B, van Zwieten R, et al. G‐>T transition at cDNA nt 110 (K37Q) in the PKLR (pyruvate kinase) gene is the molecular basis of a case of hereditary increase of red blood cell ATP. Hum Mutat. 1997;9(3):282-285.
62. Viprakasit V, Ekwattanakit S, Riolueang S, et al. Mutations in Kruppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expression. Blood. 2014;123(10):1586-1595.
63. Beutler E, Gelbart T. Estimating the preva- lence of pyruvate kinase deficiency from the gene frequency in the general white popula- tion. Blood. 2000;95(11):3585-3588.
64.Carey PJ, Chandler J, Hendrick A, et al. Prevalence of pyruvate kinase deficiency in northern European population in the north of England. Northern Region Haematologists Group. Blood. 2000;96(12): 4005-4006.
65. Secrest MH, Storm M, Carrington C, et al. Prevalence of pyruvate kinase deficiency: a systematic literature review. Eur J Haematol. 2020 Apr 12. [Epub ahead of print]
66. van Bruggen R, Gualtieri C, Iliescu A, et al. Modulation of malaria phenotypes by pyru- vate kinase (PKLR) variants in a Thai popu- lation. PLoS One. 2015;10:e0144555.
67. Min-Oo G, Fortin A, Tam MF, et al. Pyruvate kinase deficiency in mice protects against malaria. Nat Genet. 2003;35(4):357- 362.
68.Ayi K, Min-Oo G, Serghides L, et al. Pyruvate kinase deficiency and malaria. New Eng J Med. 2008;358(17):1805-1810.
69. Qidwai T, Jamal F, Singh S. Exploring puta- tive molecular mechanisms of human pyru- vate kinase enzyme deficiency and its role in resistance against Plasmodium falciparum malaria. Interdiscipl Sci. 2014;6(2):158-166.
70. van Wijk R, Huizinga EG, van Wesel AC, et al. Fifteen novel mutations in PKLR associat- ed with pyruvate kinase (PK) deficiency: structural implications of amino acid substi- tutions in PK. Hum Mutat. 2009; 30(3):446- 453.
71.Jaouani M, Manco L, Kalai M, et al. Molecular basis of pyruvate kinase deficien- cy among Tunisians: description of new mutations affecting coding and noncoding regions in the PKLR gene. Int J Lab Hematol. 2017;39(2):223-231.
72. Christensen RD, Yaish HM, Johnson CB, et al. .Six children with pyruvate kinase defi- ciency from one small town: molecular char- acterization of the PK-LR gene. J Pediatr. 2011;159(4):695-697.
73.Lakomek M, Winkler H, Pekrun A, et al. Erythrocyte pyruvate kinase deficiency. The influence of physiologically important metabolites on the function of normal and defective enzymes. Enzyme Protein.
2228
haematologica | 2020; 105(9)